66742-57-2

Basic information

• Product Name: 4-(3-FLUORO-BENZYLOXY)-BENZALDEHYDE
• Synonyms: 4-[(3-fluorophenyl)methoxy]-Benzaldehyde;Benzaldehyde, 4-[(3 -fluorophenyl)Methoxy]-;Safinamide mesylate Intermediate;Safinamide mesylate Intermediate 1
• CAS NO: 66742-57-2
• Molecular Formula: C₁₄H₁₁FO₂
• Molecular Weight: 230.23
• Product Categories: Intermediate
• Mol File: 66742-57-2.mol
• Article Data: 18

Chemical Properties

• Melting Point: 46.0 to 50.0 °C
• Boiling Point: 265°C/3mmHg(lit.)
• Flash Point: 167.6°C
• Appearance: /
• Density: 1.211g/cm³
• Vapor Pressure: 1.83E-05mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-(3-FLUORO-BENZYLOXY)-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-FLUORO-BENZYLOXY)-BENZALDEHYDE(66742-57-2)
• EPA Substance Registry System: 4-(3-FLUORO-BENZYLOXY)-BENZALDEHYDE(66742-57-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 66742-57-2(Hazardous Substances Data)

Usage

Uses

4-(3-Fluorobenzyloxy)benzaldehyde is useful for organic reactions and synthesis.

InChI:InChI=1/C14H11FO2/c15-13-3-1-2-12(8-13)10-17-14-6-4-11(9-16)5-7-14/h1-9H,10H2

Upstream product

• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 99-96-7 4-hydroxy-benzoic acid 
• 123-08-0 4-hydroxy-benzaldehyde 
• 1000370-26-2 3-fluorobenzyl methanesulfonate 
• 456-42-8 m-fluorobenzyl chloride 

Downstream Products

• 174756-44-6 FCE 28073 
• 1161738-35-7 (R)-2-[4-(3-fluorobenzyloxy)benzylideneamino]propanamide 
• 133865-89-1 safinamide 
• 1000370-31-9 (S)-2-[4-(3-fluorobenzyloxy)benzylideneamino]propanamide 
• 202825-46-5 safinamide mesylate 
• 1613166-30-5 3-[4-(3-fluorobenzyloxy)phenyl]isoxazole-5-carboxylic acid 
• 1613166-29-2 3-[4-(3-fluorobenzyloxy)phenyl]isoxazole-5-carboxylic acid ethyl ester 

Relevant articles and documents

A Two Hour Synthesis of the Anti-Parkinson Drug Safinamide Methanesulfonate

The critical moment of the COVID-19 outbreak requires a real-time supply of therapeutic agents. Thus, time economy in the synthesis of biologically active compounds has become increasingly decisive. In this work, we developed a two hour synthesis of the a

Morpholine amide derivative and application thereof

The invention discloses a morpholine amide derivative and application thereof, and particularly relates to a novel morpholine amide derivative and a pharmaceutical composition containing the compound.The invention also relates to a method for preparing th

Potential anti-neuroinflammatory NF-кB inhibitors based on 3,4-dihydronaphthalen-1(2H)-one derivatives

Nuclear factor kappa B (NF-кB) inhibition represents a new therapeutic strategy for the treatment of neuroinflammatory diseases. In this study, a series of 3,4-dihydronaphthalen-1(2H)-one (DHN; 6a-n, 7a-c) derivatives were synthesised and characterised by NMR and HRMS. We assessed the toxicity and anti-neuroinflammatory properties of these compounds and found that 6m showed the greatest anti-neuroinflammatory properties, with relatively low toxicity. Specifically, 6m significantly reduced reactive oxygen species production, down-regulated the expression of NOD-like receptor pyrin domain-containing protein 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1 and prevented lipopolysaccharide-stimulated BV2 microglia cells polarisation towards an M1 phenotype. Furthermore, 6m significantly decreased IκBα and NF-кB p65 phosphorylation, thus inhibiting the NF-кB signalling pathway. This suggests that 6m may be explored as a functional anti-neuroinflammatory agent for the treatment of inflammatory diseases in the central nervous system, such as multiple sclerosis, traumatic brain injury, stroke and spinal cord injury.